CXCR4 and breast carcinoma: This data strongly suggest that CXCR4/PDGFRα is a potential target of NT21MP in the inhibition of the EMT process in breast cancer and demonstrate that PR cells with NT21MP treatment were significantly more sensitive to paclitaxel-induced cell growth inhibition.